Astrazeneca (AZN) Enterprise Value (2016 - 2025)
Astrazeneca (AZN) has 3 years of Enterprise Value data on record, last reported at -$5.7 billion in Q4 2025.
- For Q4 2025, Enterprise Value fell 2.85% year-over-year to -$5.7 billion; the TTM value through Dec 2025 reached -$5.7 billion, down 2.85%, while the annual FY2025 figure was -$5.7 billion, 2.85% down from the prior year.
- Enterprise Value reached -$5.7 billion in Q4 2025 per AZN's latest filing, down from -$5.5 billion in the prior quarter.
- Across five years, Enterprise Value topped out at -$1.3 billion in Q4 2023 and bottomed at -$5.7 billion in Q4 2025.
- Average Enterprise Value over 3 years is -$4.2 billion, with a median of -$5.5 billion recorded in 2024.
- Peak YoY movement for Enterprise Value: crashed 318.26% in 2024, then dropped 2.85% in 2025.
- A 3-year view of Enterprise Value shows it stood at -$1.3 billion in 2023, then plummeted by 318.26% to -$5.5 billion in 2024, then decreased by 2.85% to -$5.7 billion in 2025.
- Per Business Quant database, its latest 3 readings for Enterprise Value were -$5.7 billion in Q4 2025, -$5.5 billion in Q4 2024, and -$1.3 billion in Q4 2023.